Logo
A

Amicus Therapeutics

0 employees

We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. Amicus is the Latin word for friend. This name signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. Our company was founded by an entrepreneur who embarked on a life-long journey to transform the lives of those living with devastating conditions when two of his children were diagnosed with a rare disease. That spirit of empathy, compassion, and tenacity permeates our culture and influences all aspects of our approach to advancing cutting-edge technologies. Building on our core beliefs, our mission-focused behaviors help us define and shape our culture; drive performance and innovation; inform development and growth; and attract, energize, and retain the right talent. By championing mission-dedication, innovation, performance, and integrity, we are united by our passion for making a difference and committed to pushing ideas as far and as fast as possible. Our global footprint spans over 20 countries, including our global headquarters in Princeton, NJ and international headquarters in Marlow, UK. Additional international office locations include Australia, Canada, France, Japan, Germany, Italy, The Netherlands, and Spain. More information about Amicus and our career opportunities can be found at www.amicusrx.com.

Investor insights

Funding rounds participated in

$30M sweet spot round size

Investor type

Public Company

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2002

Funding rounds raised

Total raised

$30M

from 1 investors over 1 rounds

A

Amicus Therapeutics raised $30M on November 2, 2023

Investors: Blackstone Life Sciences

FAQ